Max Drawdown (5Y) Chart

Historical Max Drawdown (5Y) Data

View and export this data back to 2017. Start Trial.
Date Value
September 30, 2026 98.49%
August 31, 2026 98.49%
July 31, 2026 98.49%
June 30, 2026 98.49%
May 31, 2026 98.49%
April 30, 2026 98.49%
March 31, 2026 98.49%
February 28, 2026 98.49%
January 31, 2026 98.49%
December 31, 2025 98.49%
November 30, 2025 98.49%
October 31, 2025 98.49%
September 30, 2025 98.49%
August 31, 2025 98.49%
July 31, 2025 98.49%
June 30, 2025 98.49%
May 31, 2025 98.49%
April 30, 2025 98.49%
March 31, 2025 98.49%
February 28, 2025 98.49%
January 31, 2025 98.49%
December 31, 2024 98.49%
November 30, 2024 98.49%
October 31, 2024 98.49%
September 30, 2024 98.49%
Date Value
August 31, 2024 98.49%
July 31, 2024 98.49%
June 30, 2024 98.49%
May 31, 2024 98.49%
April 30, 2024 98.49%
March 31, 2024 98.49%
February 29, 2024 98.49%
January 31, 2024 98.49%
December 31, 2023 98.49%
November 30, 2023 98.49%
October 31, 2023 98.49%
September 30, 2023 98.49%
August 31, 2023 98.49%
July 31, 2023 98.49%
June 30, 2023 98.49%
May 31, 2023 98.49%
April 30, 2023 98.49%
March 31, 2023 98.49%
February 28, 2023 98.49%
January 31, 2023 98.49%
December 31, 2022 98.49%
November 30, 2022 98.49%
October 31, 2022 98.49%
September 30, 2022 98.49%
August 31, 2022 98.49%

Max Drawdown Definition

Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.

Read full definition.

Max Drawdown (5Y) Range, Past 5 Years

View Max Drawdown (5Y) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Max Drawdown (5Y) Benchmarks

View Max Drawdown (5Y) Benchmarks
Start Trial
MediGene AG 98.50%
BioNTech SE 82.24%
Immatics NV 77.36%
Arrowhead Pharmaceuticals, Inc. 88.96%
Oncolytics Biotech, Inc. 92.83%